Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 04.05.2026 1 Anticancer Res 1 BJU Int 3 BMC Cancer 1 BMC Urol 1 Cancer Imaging 1 Cancer Lett 2 Clin Cancer Res 1 Eur Radiol 2 Eur Urol 1 Hum Pathol 3 Int J Urol 2 J Nucl Med 2 J Urol 2 Lancet Oncol 1 Nat Rev Urol 4 Prostate 2 Radiology 2 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Anticancer Res

1. RADES D, Narvaez-Wolf CA, Zwaan IC, Vestergard-Madsen C, et al
   A Reminder App for Optimizing Bladder Filling During Radiotherapy for Prostate Cancer: A Pre-study in Healthy Volunteers.
   Anticancer Res. 2026;46:2763-2770.
   PubMed         Abstract available
   
   

   
   BJU Int

2. PICKERSGILL NA, Yu R, Vertosick EA, Fletcher SA, et al
   Diagnostic and prognostic utility of PSMA-PET/CT in node-metastatic prostate cancer.
   BJU Int. 2026 Apr 30. doi: 10.1111/bju.70280.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. XUE W, Zhang P, Quan J
   A meta-analysis of dizziness as an adverse reaction in novel endocrine therapy for advanced prostate cancer.
   BMC Cancer. 2026 May 1. doi: 10.1186/s12885-026-16101.
   PubMed         Abstract available
   
   
4. ZHOU H, Qian ZY, Chen ZH, Fan JJ, et al
   Predicting response to neoadjuvant hormonal therapy and prognostic outcomes in high-risk prostate cancer using MRI-based radiomics.
   BMC Cancer. 2026 Apr 29. doi: 10.1186/s12885-026-16015.
   PubMed        
   
   
5. BORG M, Farver-Vestergaard I, Hilberg O, Steed L, et al
   Long-term risk of depression in lung, colon, breast, and prostate cancer: a 25-year nationwide comparative study.
   BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16095.
   PubMed        
   
   

   
   BMC Urol

6. FAN J, Liu S, Li Z, Xv Y, et al
   Neoadjuvant hormone therapy plus robot-assisted radical prostatectomy improves pathologic outcomes in high-risk prostate cancer: a retrospective cohort study.
   BMC Urol. 2026 Apr 28. doi: 10.1186/s12894-026-02153.
   PubMed        
   
   

   
   Cancer Imaging

7. ATASEVER T, Babacan GB, Ekinci OB, Buyukkuscu A, et al
   Prognostic value of PSMA PET-derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
   Cancer Imaging. 2026 Apr 30. doi: 10.1186/s40644-026-01036.
   PubMed         Abstract available
   
   

   
   Cancer Lett

8. ALI A, Di Pastena F, Biziotis OD, Wang S, et al
   Canagliflozin Is a Novel Androgen Receptor Pathway Inhibitor for Castrate-Sensitive and Castrate-Resistant Prostate Cancer.
   Cancer Lett. 2026 Apr 24:218535. doi: 10.1016/j.canlet.2026.218535.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

9. SHARMA S, Mundhara N, Tekoglu E, Amaral A, et al
   Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly-Expressed, Combinatorial Therapeutic Target.
   Clin Cancer Res. 2026 Apr 29. doi: 10.1158/1078-0432.CCR-26-0642.
   PubMed         Abstract available
   
   
10. ZAIDI S, Kuo PH, Paiva Prudente T, Lacuna KP, et al
    Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.
    Clin Cancer Res. 2026;32:1766-1776.
    PubMed         Abstract available
    
    

    
    Eur Radiol

11. WAGNER T, Emberton M, Caglic I, Priftakis D, et al
    PSMA PET: the answer to MRI-occult prostate cancer... or another mirage?
    Eur Radiol. 2026 Apr 30. doi: 10.1007/s00330-026-12596.
    PubMed         Abstract available
    
    

    
    Eur Urol

12. LI T, Nguyen DD, Khondker A, Kwong JCC, et al
    Re: Personalizing Prostate Cancer Education for Patients Using an EHR-Integrated LLM Agent.
    Eur Urol. 2026 Apr 28:S0302-2838(26)02110-X. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
13. NG CPY, Light A, Ahmed H, Shah T, et al
    Reply to Ashwini Kadam, Ankit Misra and Gagan Prakash's Letter to the Editor Re: Chase Peng Yun Ng, Alexander Light, Sai Kalpitha Eragamreddy, et al. Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the
    Eur Urol. 2026 Apr 27:S0302-2838(26)02061-0. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Hum Pathol

14. AYALA A, Ding Y, Bu P, Miles B, et al
    Prognostic value of nuclear versus cytoplasmic Cyclin D1 in human prostate cancer.
    Hum Pathol. 2026 Apr 27:106138. doi: 10.1016/j.humpath.2026.106138.
    PubMed         Abstract available
    
    

    
    Int J Urol

15. MIYAZAWA Y
    Editorial Comment to Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup
    Int J Urol. 2026;33:e70488.
    PubMed        
    
    
16. KANAKI T, Hatano K, Oka T, Tani M, et al
    Myosteatosis Predicts Poor Prognosis in Patients With Castration-Resistant Prostate Cancer Treated With Enzalutamide.
    Int J Urol. 2026;33:e70476.
    PubMed         Abstract available
    
    
17. GORDON N, Patel AA, Farooq W, Watson W, et al
    Gleason Regrading After Prostatectomy-Results From the Irish Prostate Cancer Outcome Research (IPCOR) Situated in the International Context.
    Int J Urol. 2026;33:e70469.
    PubMed         Abstract available
    
    

    
    J Nucl Med

18. CHAUHAN A, Hendifar AE, El-Haddad G, Soares HP, et al
    The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond.
    J Nucl Med. 2026 Apr 30:jnumed.126.272026. doi: 10.2967/jnumed.126.272026.
    PubMed         Abstract available
    
    
19. BROSCH-LENZ J, Buther F, Oehler S, Ciamarone A, et al
    Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [(68)Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer.
    J Nucl Med. 2026 Apr 30:jnumed.125.271933. doi: 10.2967/jnumed.125.271933.
    PubMed         Abstract available
    
    

    
    J Urol

20. TOSOIAN JJ, Meyers JI, Moore B, Britton CJ, et al
    Non-Invasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison with MRI.
    J Urol. 2026 Apr 28:101097JU0000000000005095. doi: 10.1097/JU.0000000000005095.
    PubMed         Abstract available
    
    
21. GOLDSTEIN AO, Hubard LR, Bjurlin MA
    Shared Decision Making for Prostate Cancer Screening is a System Responsibility.
    J Urol. 2026 Apr 28:101097JU0000000000005094. doi: 10.1097/JU.0000000000005094.
    PubMed        
    
    

    
    Lancet Oncol

22. GRAVIS G
    An old tool for new strategies in advanced prostate cancer.
    Lancet Oncol. 2026;27:531-532.
    PubMed        
    
    
23. KAYANI M, Murphy L, Dutey-Magni P, Howlett S, et al
    On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.
    Lancet Oncol. 2026;27:625-636.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

24. PEDRANI M, Tombal B, Blanchard P, Gillessen S, et al
    Hot flushes during ADT for prostate cancer - a clinical rationale for a neurokinin 3 receptor antagonist.
    Nat Rev Urol. 2026 Apr 28. doi: 10.1038/s41585-026-01147.
    PubMed        
    
    

    
    Prostate

25. HELFAND BT, Shi Z, Mulford AJ, Tran H, et al
    Prostate Cancer, Genetic Susceptibility, and Risk of Chronic Non-Urological Complications.
    Prostate. 2026 Apr 29. doi: 10.1002/pros.70190.
    PubMed         Abstract available
    
    
26. ALAM R, Hesse D, Hubbard N, McGarrity E, et al
    A Pilot Study of (18)F-rhPSMA-7.3-PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease.
    Prostate. 2026;86:865-871.
    PubMed         Abstract available
    
    
27. PAGONIS K, Noureldin M, Lilly E, Harmouche C, et al
    Association Between Preoperative Membranous Urethral Length and Urinary Continence Recovery After Retzius Sparing Robotic Assisted Radical Prostatectomy: Results From a Retrospective Single-Center Study.
    Prostate. 2026;86:851-857.
    PubMed         Abstract available
    
    
28. GERKE TA, Tyekucheva S, Stopsack KH, Sweeney CJ, et al
    A Gene Expression Tumor Signature Optimizing Partial Area-Under-the-Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer.
    Prostate. 2026 Apr 29. doi: 10.1002/pros.70189.
    PubMed         Abstract available
    
    

    
    Radiology

29. GALGANO SJ, Turner EM
    Quantitative Post-(177)Lu-PSMA-617 SPECT/CT Analysis: Evidence for Adaptive Treatment Planning and Prognostication in Prostate Cancer.
    Radiology. 2026;319:e260836.
    PubMed        
    
    
30. AYATI N, Papa N, Crumbaker M, Subramaniam S, et al
    (177)Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.
    Radiology. 2026;319:e252672.
    PubMed         Abstract available
    
    

    
    Urology

31. KIM IE JR, Chung BI, Puri D, Soerensen SJC, et al
    Associations Between Medicaid Insurance, Facility Medicaid Share, and Guideline-Concordant Prostate Cancer Care.
    Urology. 2026 Apr 28:S0090-4295(26)00291-8. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    
32. ADLER R, Kozlov M, Viola J, Ingram J, et al
    The Risk of Benign Prostatic Hyperplasia and Prostate Cancer With Long-Term, Low Dose Finasteride Use in Adult Men with Nonscarring Alopecia: A Propensity-Matched Observational Study.
    Urology. 2026 Apr 23:S0090-4295(26)00254-2. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum